Diabetes Drugs and Cardioprotection: A Summary for Primary Care
These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.
Recent study findings—many of which were presented at the recent American Diabetes Association (ADA) 81st Scientific Sessions—have demonstrated cardioprotective effects of sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). In the slides below, find concise summaries of the more significant developments in the use of diabetes drugs for ASCVD prevention.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
